thank And joining Pete. us you, you Thank afternoon. this for all
XXXX learning optimize how diseases many the in in made throughout the the candidates a advances invest we organization. development to to opportunity target, as at patients. focus operational execution to was deliberate Kura and on well as drive took also use our year significant Although year discovery seek We drug ways, believe challenging understanding clinical past programs. we've and we best our in in to This for benefit one of was
our with momentum, of in ahead catalysts efforts Now, significant building number on enthusiasm. and the the team, we a of approach tremendous resources, year
presentation therapeutic Alpelisib plus neck leadership to AACR cell supporting in program team next-generation our an abstract transferase an inhibitor an in first months. and the for Phase Tipifarnib three support X team solid patients Phase resumed comment as a by dosed in and the Inhibitor, data Ziscamenim, liquid growth a strength mid-XXXX, our and farnesyl trial supported The the than is head anticipate from catalysts drive in accepted value billion advance at X.X By we meaningful several having XXX execution. programs financial squamous organization, enthusiasm rationale both catalysts with experienced Menin Xb and with next our combination to for expansion development cohorts and cash. for drug a named in independent X we approach newly our And of X, carcinoma; Our more expanded enrollment an position and to XX these of in tumors
for our Ziftemenab. of known a Now Beginning let's we with FDA each Inhibitor, to were Ziftemenab the receive programs. strategy hold trial clinical with comment mitigation proceed was within FDA authorization AML. or on take differentiation refractory with Menin as in an formerly syndrome. to XXX our closer enhanced The progress our look KO-XXX lifted with at Last month, pleased relapsed of agreement following partial patients
and are differentiation resumed. Cohorts a began events enhanced Inhibitor, investigators execution. of As is with our team discussed, include to associated intervention. so ensure future patients monitoring, Highlights blasts. Screening to recommendations awareness, heightened an may our therapeutic to we're resolve for known and occur. fully and which has be Xb our and effect induce of for address syndrome issue, FDA holidays our speaks proud I'm that report of enrollment in they strategy to including Menin in number focus working for which the site expansion prepared pleased leukemic to operational to aggressive earnest, new informed All should very diligently Phase the patient this mitigation we've differentiation of increased physicians agents, on-target with over on
clinical to remain hold, patients remember and we're enrolled as the While Ziftameneb. partial that patients already study, tolerability as by and to seeing were study to new activity profile, the our important clinical it's continue to well the to we're we with excited be eligible encouraged recruit during Xb safety Phase on
Looking second quarter, forward, tolerability, which for to we patients the after in and will we Pharmacokinetics as in Xb assess cohort patients the as expect by complete each XX the study efficacy. well safety Phase enrollment and exposure, of
all with to II the earlier reserved goal the giving the from Xb is meeting registration Our in a identified from subsequent including the potential identify and report data a third KOMET-XXX United us larger X and fourth Phase to sites Once Phase by at we've continue combination from for recommended top-line dose medical the we recommended that X contribute the data access in a quarter plan Phase in flexibility into therapy data we transition development to quarter. portion patients have patient selected of additional register designing KOMET-XXX. the of anticipation an dose, portion patients the X the momentum of opportunities, to comprehensive strategy X to also States to treated the Phase of KOMET-XXX. while as to up add the Ziftemenab We maintain will XX We're cohort in lines enrolling enabling the in Xb us Phase more believe to Phase builds the quickly. recommended Meanwhile, Phase we continue study, Europe potential to while of population. monotherapy on dose updated
later to for this Ziftemenab expect development say to much regarding more our strategy We have year. global
let's Inhibitor our turn to Farnesyl Transferase programs. our attention Now,
continue potential potentially We transferase opportunities view to oncology. commercial multiple valuable inhibition in therapeutic to franchise, deliver with farnesyl one a and as
as HRAS of effort Squamous advanced a with focused directed Mutant ongoing neck HNSCC, patients most carcinoma, head Our cell and or on trial our registration monotherapy. through is Tipifarnib NHN
the body larger support and combinations, combination Tipifarnib at Among subsets. growing we've prioritized the of of directed Inhibitor kinase a of genetic regimens clinical PIX combination these data Tipifarnib and in potential addition, an alpha. development of In preclinical
trial, are as and with Mutant the PIX-Kinase X-X alone. dose patients patients for meaningfully believe with Preclinical breast PIX-Kinase much and Furthermore, combining treat of that dysregulated Last a with potential inhibitor in relative HNSCC. as that demonstrated to HNSCC. Tipifarnib a in in Phase codependent population the first study approved has collaboration in PIKXCA Our we it with patients is PIKXCA this with Alpelisib, we patient HNSCC. HNSCC, activity and activity cancer Tipifarnib the to encouraging In of evidence December, combination inhibiting of with evaluate combination target the Tipifarnib either XX% Alpelisib alpha oncogenes potential an with better a has HNSCC, clinical suggests to to we in to the alpha PIX-Kinase cohort total data Tipifarnib HRS announced continued by HNSCC, inhibitor, Alpelisib the dependent HRS expression who we to alpha with Novartis which study and combination call year, in initial have includes we provide expect quarter patients antitumor the of over third clinical this initiate to year. increase cohort PIKXCA we're a patients has and current The of enrollment. of pleased pace and addressable
Tipifarnib studies our we opportunity has Our inhibitors, in believe April. Finance identified collaborators senior patients, in our we goal progress I year-end. and our Toward are dose and candidate year, the opportunity De providers, shareholders. Communications, is preliminary meantime, healthcare of our to upcoming upon believe our demonstrates neck escalation, of of with create and perform lead mission. cell preclinical the and experience, three for of Last tumor to supporting farnesylated unmet we to from creation. genetically emerging value that believe collaborations, cancer presentation the and inhibitor Leoni farnesyl an identify Development, sharing the indications non-small Dr. to transferase Research about onset the some promotions, accepted this we of detailed forward to expansion may program. for each be at look a Investor information head Doyle to nominated Dose advance We're [Indiscernible] evaluation expanded our address cancer academic Annual high we've data X key position planning opportunities to and next-generation, is proteins Depending for Clinical recently pharmacokinetic President a focus the in Association driven non-small while to In support team solid realize current enabling work, operational Meeting. abstract on combination internal in I exciting and This recommended potential Corporate help Vice tolerability, trial our through with in were President improved target American clinical Spain our clinical value through represent significant KO-XXXX to large first KO-XXXX. Cancer more farnesyl of novel initial Senior own informed leadership lung KO-XXXX been has the and Vice safety, excited to the enriched resistance. one opportunities extensive physiochemical recently of And network lung a continuing properties IND Senior and of was we programs Phase drug for for of in transferase to We we the to Tom financial potential activity and efforts Pete regiments Vice cell our President that end, leadership, as Senior by designed KO-XXXX Meanwhile Relations, have Accounting. relative and in potency, combination. patients value. with academic Mollie on development resources delaying by that our schedule Based on provide significant and Tipifarnib. of combination need
Senior President our Regulatory to of been our team. has Scalfarotto, In added addition, Affairs, Vice senior Nic also leadership
as as their decision to Mark family. closer three opportunity strong position. this opportunity for than assumed Kura, to like of an important leadership Officer, ensuring his an within Mali, growth. and We exciting next Chief who to in down Nick, to years These to played his in has pursue to role additions service more our financial senior which thank our stepped Principal contribution ability well role take cultivating of promotion, over he his the during that, I'd Tom endeavors. I a be help recently into Tom a to wish team intentional results. are family Financial of closer the our Officer Grasso, his about our Marc its to lead to also connection and will I from Accounting as in In to respect confidence well Pete, discussion phase us of Business organization. financial with and for Chief our of Tom, call significant talent reflect his turn future now the him With
